Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.13716
Abstract: Essentials Acquired thrombotic thrombocytopenic purpura (aTTP) is linked with significant morbidity/mortality. Caplacizumab's effect on major thromboembolic (TE) events, exacerbations and death was studied. Fewer caplacizumab‐treated patients had a major TE event, an exacerbation, or died… read more here.
Keywords: thromboembolic events; events exacerbations; acquired thrombotic; thrombotic thrombocytopenic ... See more keywords